The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD). Twenty-four patients with MSA-p and 26 cases with PD entered the study. They were submitted to treatments of clonidine, arginine and a combination of the two in a random manner on three different nonconsecutive days. The GH peak in serum at different times was evaluated and used as a primary variable for analysis of the stimulation test. By ROC analysis, we compared the sensitivity and specificity of tests of clonidine, arginine and both combined. After clonidine administration, the maximal average was significantly lower in patients with MSA-p than in those with PD (3.62 +/- 0.81 vs. 6.91 +/- 1.13; P < 0.05) with a sensitivity and specificity of 82.61 and 76.92%. After arginine administration, the maximal average GH concentration in serum at 30 min was also significantly lower in patients with MSA-p than in those with PD (4.07 +/- 0.80 vs. 7.89 +/- 1.29; P < 0.05) with a sensitivity and specificity of 78.26 and 73.08%. The sensitivity and specificity in differentiating MSA-p from PD was higher in the clonidine GH stimulation test than in the arginine GH stimulation test. However, when the clonidine and arginine were applied combined, the contrast of the maximal average GH concentration in serum in two groups was markedly increased (5.02 +/- 1.12 vs. 10.75 +/- 1.11; P < 0.05) with a sensitivity and specificity of 73.91 and 92.31%, and the specificity was notably increased in the combined GH stimulation test. Compared to the arginine GH stimulation test, the clonidine GH stimulation displayed a higher sensitivity and specificity; combined GH stimulation test of clonidine plus arginine could significantly enhance the specificity in differential diagnosis of MSA-p from PD.
Zhang
Kezhong
K
Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zeng
Yanyin
Y
Song
Chunjie
C
Fu
Yu
Y
Wan
Qi
Q
D000368:Aged; D001120:Arginine / Q000008:administration & dosage; D003000:Clonidine / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004338:Drug Combinations; D005260:Female; D019382:Human Growth Hormone / Q000096:biosynthesis / Q000097:blood*; D006801:Humans; D008297:Male; D019578:Multiple System Atrophy / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology; D020734:Parkinsonian Disorders / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology; D012680:Sensitivity and Specificity; D015854:Up-Regulation / Q000502:physiology
D004338:Drug Combinations; D019382:Human Growth Hormone; D001120:Arginine; D003000:Clonidine
J Neurol Sci. 1979 Sep;43(1):59-82
521829
Clin Med Res. 2006 Dec;4(4):322-5
17210980
Muscle Nerve. 1997 Nov;20(11):1396-403
9342156
Neurology. 1999 Sep 22;53(5):1020-5
10496261
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
1564476
J Neurol. 2000 Nov;247(11):853-6
11151417
Lancet. 1999 Apr 17;353(9161):1329-30
10218537
Mov Disord. 2002 Nov;17(6):1242-7
12465063
Ann Neurol. 1998 Feb;43(2):156-63
9485056
Mov Disord. 2008 Jan 30;23(2):190-4
18044703
Physiol Rev. 1999 Apr;79(2):511-607
10221989
J Neurol. 2002 Sep;249(9):1206-10
12242540
Mov Disord. 2000 Nov;15(6):1158-67
11104200
Neurology. 2000 Feb 8;54(3):697-702
10680806
Lancet. 1997 Jun 28;349(9069):1877-81
9217760
Mov Disord. 1999 May;14(3):430-5
10348465
Clin Endocrinol (Oxf). 2005 Apr;62(4):428-33
15807873
Endocr Rev. 1998 Dec;19(6):717-97
9861545
Arch Neurol. 1995 Mar;52(3):294-8
7872884